Ferrer M, Mourikis N, Davidson EE, Kleeman SO, Zaccaria M, Habel J, et al
For the SGLT2i cohort, we included patients who had received an SGLT2i for at least 6 months (Fig
(68), which reported that sweet taste receptor antagonism with lactisole reduced GLP-1 and PYY secretion but had no effect on CCK release, highlighting pathway-specific effects
Verify any prescribers credentials through the Federation of State Medical Boards directory at fsmb.org
While current methods have transformed modern therapeutics, they remain constrained by poor oral bioavailability, stability challenges, cold-chain dependence, and limited patient acceptability associated with injectable administration, according to a review in AAPS PharmSciTech